MétaCan
Menu
Back to cohort
Record W2399161841 · doi:10.1093/neuonc/nov205.12

ATNT-12PHASE I, TWO-STAGE, OPEN-LABEL, DOSE-ESCALATION STUDY OF BUPARLISIB (BKM120) IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE (TMZ) AND WITH CONCOMITANT RADIATION THERAPY (RT) AND TMZ IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)

2015· article· en· W2399161841 on OpenAlexaff
Jordi Rodón, Mark Rosenthal, Warren Mason, Pedro Pérez Segura, J. Thaddeus Beck, Holger W. Hirte, John DeGroot, Lucia Trandafir, Nathalie Pognan, Lin Yang, Charu Kanwal, Patrick Y. Wen

Bibliographic record

VenueNeuro-Oncology · 2015
Typearticle
Languageen
FieldMedicine
TopicGlioma Diagnosis and Treatment
Canadian institutionsJuravinski Cancer CentrePrincess Margaret Cancer Centre
Fundersnot available
KeywordsMedicineConcomitantInternal medicineAdjuvantTemozolomideGastroenterologySurgeryOncologyChemotherapy

Abstract

fetched live from OpenAlex

BACKGROUND: Phase I, two-stage study of buparlisib combined with standard-of-care (RT + TMZ followed by adjuvant TMZ) in newly diagnosed GBM. METHODS: Stage I evaluated buparlisib with adjuvant TMZ in 28-day treatment cycles after prior RT + TMZ treatment. Stage II evaluated buparlisib with concomitant RT + TMZ and then adjuvant TMZ. In the concomitant phase, buparlisib was administered at two schedules: 60mg/40mg/QD or 40mg D1–5/Q7, in combination with RT (2.5 Gy/day) + TMZ 75mg/m2/day over 42 days. In the adjuvant phase, buparlisib was administered at 80mg/QD during Cycle 1 with TMZ 150mg/m2 D1–D5/Q28 (A1), and at 60mg/80mg/QD during Cycles 2–12 with TMZ 200mg/m2 on D1–D5/Q28 (A2). Dose-escalation was guided by a Bayesian logistic regression model with overdose control principle. Primary study objectives were to identify buparlisib dose-limiting toxicities (DLTs) and to determine the recommended Phase II dose (RP2D). RESULTS: Adjuvant: Of 16 patients treated, six developed DLTs, including three DLTs in A1: Grade(G) 3-hyperglycemia, G3-anxiety, G3-intermittent confusion (1 patient each) at 80mg/QD; and three in A2: G2-hyperglycemia (1 patient) at 60mg/QD, G4-platelet count decrease and G4-thrombocytopenia (1 patient each) at 80mg/QD. Concomitant: Of 22 patients treated, seven developed DLTs: G4-thrombocytopenia (2 patients) at 60mg/QD, G4-lipase elevation (2 patients) and G2-thrombocytopenia (1 patient) at 40mg/QD, G3-decreased mood (1 patient) and G4-decreased platelet count (1 patient) at 40mg D1–5/Q7. Twenty-three patients (60.5%) experienced study-drug-related G3/4 adverse events (AEs) including hyperglycemia, neutropenia, thrombocytopenia (13.2% each), and lipase increase (10.5%). Twenty-nine patients discontinued treatment due to AEs (44.7%), disease progression (26.3%), and withdrawal of consent (5.3%). CONCLUSION: RP2D of buparlisib for the adjuvant phase in combination with TMZ was defined as 80mg/QD. RP2D of buparlisib plus RT + TMZ was not determined due to challenging safety at all doses/schedules. Exposure of buparlisib with RT + TMZ was slightly lower than that of single-agent buparlisib. Anti-tumor activity is under evaluation and will be reported.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.016

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.001
Meta-epidemiology (narrow)0.0030.001
Meta-epidemiology (broad)0.0030.002
Bibliometrics0.0010.001
Science and technology studies0.0010.001
Scholarly communication0.0010.002
Open science0.0020.001
Research integrity0.0020.005
Insufficient payload (model declined to judge)0.0050.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.029
GPT teacher head0.314
Teacher spread0.285 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2015
Admission routes1
Has abstractyes

Explore more

Same venueNeuro-OncologySame topicGlioma Diagnosis and TreatmentFrench-language works237,207